We are live on ! Find out more
NCM

Nantahala Capital Management Portfolio holdings

AUM $2.72B
1-Year Est. Return 121.58%
This Fund
S&P 500
This Quarter Est. Return
-6.99%
1 Year Est. Return
+121.58%
3 Year Est. Return
+308.64%
5 Year Est. Return
+308.9%
10 Year Est. Return
+2,888.73%
AUM
$1.71B
AUM Growth
-$39.6M
Cap. Flow
+$72.3M
Cap. Flow %
4.23%
Top 10 Hldgs %
57.63%
Holding
146
New
23
Increased
28
Reduced
39
Closed
16

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$28.5M
2
ESTA icon
Establishment Labs
ESTA
+$27.8M
3
PTON icon
Peloton Interactive
PTON
+$16.6M
4
SVRA icon
Savara
SVRA
+$15.3M
5
OPTN
OptiNose
OPTN
+$12.2M

Top Sells

Rank Stock Value
1
CASH icon
Pathward Financial
CASH
+$25.3M
2
LYRA
LYRA THERAPEUTICS INC
LYRA
+$17.5M
3
RDVT icon
Red Violet
RDVT
+$13.4M
4
DYN icon
Dyne Therapeutics
DYN
+$12.4M
5
GDEN
Golden Entertainment
GDEN
+$9.92M

Sector Composition

Rank Sector Weight
1 Healthcare 39.62%
2 Consumer Discretionary 7%
3 Financials 3.63%
4 Communication Services 3.53%
5 Technology 1.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNTX
101
Rein Therapeutics
RNTX
$67.9M
$1.29M 0.08%
464,367
+209,367
+82% +$860K
GORV
102
DELISTED
Lazydays
GORV
$1.27M 0.07%
+16,667
New +$1.77M
VSTM icon
103
Verastem
VSTM
$615M
$1.19M 0.07%
+400,000
New +$3.3M
QURE icon
104
CALL
uniQure
QURE
$3.2B
$1.09M 0.06%
243,000
– –
SSKN
105
DELISTED
Strata Skin Sciences
SSKN
$933K 0.05%
303,917
-5,065
-2% -$20.5K
KPRX icon
106
Kiora Pharmaceuticals
KPRX
$11.4M
$887K 0.05%
211,110
-1
-0% -$5
PERF icon
107
Perfect Corp
PERF
$190M
$847K 0.05%
419,133
+219,133
+110% +$476K
OKUR
108
OnKure Therapeutics
OKUR
$164M
$846K 0.05%
+54,780
New +$929K
APRE icon
109
Aprea Therapeutics
APRE
$7.98M
$837K 0.05%
205,760
– –
NKLA
110
DELISTED
Nikola Corporation Common Stock
NKLA
$819K 0.05%
+99,999
New +$1.78M
NMTC icon
111
NeuroOne Medical Technologies
NMTC
$13.6M
$761K 0.04%
158,494
-41,325
-21% -$260K
KRYS icon
112
PUT
Krystal Biotech
KRYS
$9.81B
$716K 0.04%
+3,900
New +$655K
IMTXW
113
DELISTED
Immatics N.V. Warrants
IMTXW
$688K 0.04%
248,506
-310,471
-56% -$873K
GOSS icon
114
Gossamer Bio
GOSS
$86.1M
$623K 0.04%
672,856
– –
RILY icon
115
BRC Group Holdings
RILY
$292M
$423K 0.02%
23,976
-38,544
-62% -$991K
EVOK
116
DELISTED
Evoke Pharma
EVOK
$357K 0.02%
56,250
– –
IWM icon
117
iShares Russell 2000 ETF
IWM
$81.5B
$308K 0.02%
+1,516
New +$306K
LADR
118
Ladder Capital
LADR
$1.22B
$289K 0.02%
25,631
– –
FBIO icon
119
Fortress Biotech
FBIO
$91.4M
$262K 0.02%
153,152
-125,000
-45% -$227K
EWTX icon
120
Edgewise Therapeutics
EWTX
$4.84B
$241K 0.01%
13,371
– –
ANTX icon
121
AN2 Therapeutics
ANTX
$213M
$211K 0.01%
98,278
– –
BMTX
122
DELISTED
BM Technologies, Inc.
BMTX
$171K 0.01%
76,034
– –
XGN icon
123
Exagen
XGN
$161M
$108K 0.01%
59,316
-14,990
-20% -$25.4K
LUCD icon
124
Lucid Diagnostics
LUCD
$183M
$104K 0.01%
126,362
-23,336
-16% -$19.8K
TACT icon
125
Transact Technologies
TACT
$57.6M
$75.9K ﹤0.01%
20,123
-3,807
-16% -$16K
2 3 4
5
6

Similar funds

TAM
Timucuan Asset Management Jacksonville, Florida $2.72B AUM 4.95% 1-Year Est. Return
XL
XN LP New York $2.72B AUM 46.67% 1-Year Est. Return
NB
Nicolet Bankshares Green Bay, Wisconsin $2.71B AUM 17.55% 1-Year Est. Return
PA
Profund Advisors Bethesda, Maryland $2.72B AUM 47.27% 1-Year Est. Return
BCM
Bowie Capital Management Richardson, Texas $2.71B AUM 5.42% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return
GC
Giverny Capital Montreal, Quebec, Canada $2.73B AUM 14.09% 1-Year Est. Return

Nantahala Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Nantahala Capital Management held 146 positions worth $1.71B, down 2.3% from $1.75B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Nantahala Capital Management deployed $72.3M of net new capital in Q2 2024, opening 23 new positions and adding to 28 existing holdings. Its largest new stake was The Bancorp: 337,846 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, up from 37% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was Pathward Financial, an estimated $25.3M trimmed.

  • Nantahala Capital Management's largest Q2 2024 buy was The Bancorp: 337,846 shares worth $12.8M.
  • Nantahala Capital Management added most to Soleno Therapeutics in Q2 2024, an estimated $28.5M increase.
  • Nantahala Capital Management's biggest Q2 2024 reduction was Pathward Financial, cutting an estimated $25.3M.
  • Nantahala Capital Management fully exited LYRA THERAPEUTICS INC in Q2 2024, selling an estimated $17.5M.
  • Nantahala Capital Management's ten largest holdings make up 58% of its $1.71B portfolio in Q2 2024.
  • Nantahala Capital Management opened 23 new positions and closed 16 in Q2 2024.
  • Nantahala Capital Management's portfolio value fell 2.3% quarter-over-quarter to $1.71B.

Based on Nantahala Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.